Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Background and Objective
Ticagrelor, a reversible P2Y
12
platelet inhibitor, is under investigation as a sickle cell disease (SCD) therapy in children. HESTIA1 (NCT02214121) was the first ticagrelor study generating pharmacokinetic (PK), pharmacodynamic (PD, P2Y
12
reactivity units [PRU]), and safety data in 45 pediatric SCD patients...
Alternative Titles
Full title
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2490297022
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2490297022
Other Identifiers
ISSN
0312-5963
E-ISSN
1179-1926
DOI
10.1007/s40262-019-00758-0
